Weight loss and diabetes jabs linked to potentially fatal side effect
In recent months, British regulators received around 400 reports of acute pancreatitis associated with GLP of 1 receptoragonist medicines - which is usually prescribed for type 2 diabetes and has also been used for weight loss. These include brand names such as Maunzaro (Tirzepetide), Ozmpic, Vegovi (both Semglutide) and Liraglutid. Acute pancreatitis is an intensive inflammation of the pancreas and can be a threat to life. Although considered rare, these cases are GLP. 1 represents about 1 in 100 users of medicines. Dangerous, more than a quarter of reports reported in 2025 alone. Recognizing the potential danger, British medicines and health products Regulatory Agency (MHRA) has initiated a study on some individuals may be more genetically uncertain for the development of pancreatitis while taking these medicines. To detect this hypothesis, MHRA and Genomics England have formed a team to create a yellow short biobank. This new initiative will collect genetic samples from affected patients to seek the underlying markers who can predict high risk. If successful, such forecast genetic testing may allow doctors to identify these drugs before deciding, and then preventing one -third of future events and reducing stress on the NHS. Both drug producers - Lily and Novo Nordisk - have responded to their commitment to protect the patient. They emphasize that when used properly during medical supervision, GLP '1 Therapy Forms are still important. However, they also emphasize the importance of monitoring and assessing patients properly before and during treatment. In summary, while GLP, 1 medication provides great benefits for overweight or diabetic patients, newer data
Read full Story »Disclaimer: This preview includes title, image, and description automatically sourced from the original website (news.sky.com) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
